Abstract： To analyze the value of BRAFv600E gene detection in guiding papillary thy-roid carcinoma surgery for Zone Ⅵ lymph node dissection. Methods From March 2013 to March 2017, 305 patients with thyroid papillary carcinoma admitted were selected as the malignant tumor group,inclu-ding 65 males and 240 females,aged(42. 8 ± 11. 3)years old,ranging from 23 to 74 years old. The other 85 patients with thyroid benign tumor during the same period were selected as the thyroid benign tumor group, including 17 males and 68 females,aged(40. 3 ± 10. 6) years,ranging from 22 to 72 years. Real-time fluo-rescence quantitative polymerase chain reaction(PCR)was used to detect BRAFv600E gene mutation in fresh tissue pathological specimens of the two groups of patients,and the BRAFv600E gene mutation rate was com-pared in the two groups of patients to analyze its correlation with CEUS examination and lymph node metas-tasis. Results The BRAFv600E gene mutation rate in the malignant tumor group was 84. 3% (257/305) . The gene mutation rate in the thyroid benign tumor group was 0(0/85),and the difference was statistically significant(P<0. 05). Patients in the malignant tumor group were divided into two groups according to the occurrence of BRAFv600E gene mutation. The 168 patients in the mutation group had metastasis, and the lymph node metastasis rate was 65. 4% (168/257). In the non-mutated group,8 patients had metastasis, and the lymph node metastasis rate was 16. 7% (8/48),with statistically significant difference(P<0. 05) . Two groups of patients with lymph node metastasis main area is located inⅥdistrict. There was no statisti-cally significant difference in the enhancement mode between the mutant group and the non-mutant group(P>0. 05),and the main performance of patients in both groups was weak enhancement. In the malignant tumor group,the rate of cervical lymph node metastasis in patients with weak enhancement was significantly lower than those with equal enhancement and high enhancement,with statistically significant difference(P<0. 05). Conclusion BRAFv600E mutation can be used as a predictor of thyroid papillary carcinoma invasive to evaluate whether lymph node cleaning the neck Zone Ⅵ.